Rydex Biotechnology Fund Class H RYOAX

Morningstar Medalist Rating
  • NAV / 1-Day Return$72.55  /  −0.51%
  • Fund Size$153.6M
  • Adjusted Expense Ratio1.630%
  • Net Expense Ratio1.630%
  • Fee Level: DistributionHigh
  • Share Class TypeNo Load
  • Morningstar CategoryHealth
  • Equity Style Box (Funds)Mid Blend
  • Minimum Initial Investment$2,500
  • Investment StatusOpen
  • TTM Yield0.00%
  • Turnover Ratio75%

Morningstar’s Analysis RYOAX

Will RYOAX outperform in the future?

Get our overall rating based on a fundamental assessment of the pillars below.

null Morningstar Automated Analysis

Morningstar Automated Analysis

Summary

Rydex Biotechnology H holds a quantitatively derived Negative Morningstar Medalist Rating. The rating indicates the model sees limited potential for the strategy to outperform peers on a risk-adjusted basis over a full market cycle.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings RYOAX

  • Current Portfolio Date
  • Equity Holdings—
  • Bond Holdings—
  • Other Holdings—
  • % Assets in Top 10 Holdings39.8
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

AbbVie Inc

7.8310M
Healthcare

Amgen Inc

5.758M
Healthcare

Gilead Sciences Inc

4.957M
Healthcare

Vertex Pharmaceuticals Inc

4.165M
Healthcare

Moderna Inc

3.595M
Healthcare

Natera Inc

3.104M
Healthcare

Regeneron Pharmaceuticals Inc

3.084M
Healthcare

Illumina Inc

2.674M
Healthcare

BeOne Medicines Ltd ADR

2.353M
Healthcare

Revolution Medicines Inc Ordinary Shares

2.353M
Healthcare

Sponsor Center